Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors - Shilpa Singh; Catherine E. Gleason; Min Fang; Yasmin N. Laimon; Vishal Khivansara; Shanhai Xie; Yavuz T. Durmaz; Aniruddha Sarkar; Kenneth Ngo; Varunika Savla; Yixiang Li; Muhannad Abu-Remaileh; et al. (Nature, 2025)